Head and Neck Adenocarcinoma

Observed

cbioportal

← altered in cohorts of

OR11H12

104 / 394 cases (26 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FAM243B

99 / 394 cases (25 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

KCNE1B

99 / 394 cases (25 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SMIM11B

99 / 394 cases (25 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SMIM34B

99 / 394 cases (25 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

OR11H1

98 / 394 cases (25 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

POTEH

96 / 394 cases (24 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

CNTNAP3C

89 / 394 cases (23 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SPATA31A7

89 / 394 cases (23 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SPATA31A5

88 / 394 cases (22 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FOXD4L5

87 / 394 cases (22 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

ANKRD20A4P

85 / 394 cases (22 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

CBWD5

84 / 394 cases (21 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FOXD4L4

84 / 394 cases (21 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

POTEM

84 / 394 cases (21 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

ANKRD20A3P

79 / 394 cases (20 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

ZNF658

77 / 394 cases (20 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SPATA31A3

76 / 394 cases (19 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

POTEG

70 / 394 cases (18 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

TPTE

68 / 394 cases (17 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

ANKRD20A1

67 / 394 cases (17 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

CBWD3

67 / 394 cases (17 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FAM86B2

67 / 394 cases (17 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

LINC02203

67 / 394 cases (17 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

POTEB

67 / 394 cases (17 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

POTEB3

67 / 394 cases (17 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

OR4F4

66 / 394 cases (17 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

OR4M2

66 / 394 cases (17 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

OR4N4

66 / 394 cases (17 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

RABL2B

66 / 394 cases (17 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FOXD4L3

65 / 394 cases (16 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SPATA31A6

62 / 394 cases (16 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

ACR

60 / 394 cases (15 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

DEFB130A

60 / 394 cases (15 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

POTEB2

60 / 394 cases (15 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

RRP7A

59 / 394 cases (15 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SHANK3

58 / 394 cases (15 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

WASHC1

58 / 394 cases (15 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

CHEK2

56 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

CNTNAP3B

56 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

DEFB105B

56 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

DEFB106B

56 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

DEFB107B

56 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

DENND6B

56 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FAM90A10P

56 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FAM90A17P

56 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FAM90A19P

56 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FAM90A8P

56 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FAM90A9P

56 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

HSCB

56 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

ADM2

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

ALG12

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

ARSA

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

CCDC117

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

CHKB

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

CHKB-CPT1B

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

CRELD2

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

DEFB103B

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

DEFB104A

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

DEFB104B

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

DEFB105A

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

DEFB106A

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

DEFB107A

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

DEFB4B

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FAM90A16P

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FAM90A18P

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FAM90A22P

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FAM90A23P

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

FAM90A7P

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

IL17REL

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

KLHDC7B

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

LMF2

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

MAPK11

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

MAPK12

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

MAPK8IP2

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

MIOX

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

MLC1

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

NCAPH2

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

ODF3B

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

PIM3

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

PLXNB2

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

PPP6R2

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

PRR23D1

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SBF1

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SCO2

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SELENOO

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SPAG11A

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SPAG11B

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

SYCE3

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

TRABD

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

TUBGCP6

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

TYMP

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

ZBED4

55 / 394 cases (14 %) · ssm · REBC-THYR

—

Observed

← altered in cohorts of

NRAS

39 / 496 cases (7.9 %) · ssm · thpa_tcga_gdc · largest of 4 cohorts

—

Observed

cbioportal

← altered in cohorts of

TERT

37 / 496 cases (7.5 %) · ssm · thca_tcga_pub

—

Observed

cbioportal

Head and Neck Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 54show all (up to 200)
→ investigated in trials for	Cabozantinibsmall molecule 8 trials (3 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Dabrafenibsmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 5 trials (5 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Trametinibsmall molecule 5 trials (4 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Selpercatinibsmall molecule 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Vemurafenibsmall molecule 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Cobimetinibsmall molecule 3 trials (3 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 3 trials (3 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenibsmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Pazopanibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Selumetinibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenib Tosylatesmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Adenocarcinoma	2	Observed	clinicaltrials	graph →

Head and Neck Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 54show all (up to 200)

→ investigated in trials for

Cabozantinibsmall molecule

8 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lenvatinibsmall molecule

6 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dabrafenibsmall molecule

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

5 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trametinibsmall molecule

5 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Selpercatinibsmall molecule

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vemurafenibsmall molecule

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cobimetinibsmall molecule

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sorafenibsmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pazopanibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Selumetinibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sorafenib Tosylatesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Differentiated Thyroid Gland Carcinoma

Head and Neck Adenocarcinoma studied in …STUDIED_INderived10 of 213show all (up to 200)
→ studied in	NCT05575440terminated Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 213 trials mapped (79 active)	—	—	Differentiated Thyroid Gland Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06475989Phase 3 · recruiting Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer · condition mapped CURATED_BROADER · 213 trials mapped (79 active)	—	—	Differentiated Thyroid Gland Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04522570NA · completed Thermal Ablation of Cervical Metastases From Thyroid Carcinoma · condition mapped ALIAS · 213 trials mapped (79 active)	—	—	Differentiated Thyroid Gland Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06176989Phase 2 · recruiting Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors · condition mapped CURATED_BROADER · 213 trials mapped (79 active)	—	—	Sinonasal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04544111Phase 2 · active not recruiting PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer · condition mapped ALIAS · 213 trials mapped (79 active)	—	—	Thyroid Gland Follicular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07140757recruiting Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers · condition mapped ALIAS · 213 trials mapped (79 active)	—	—	Thyroid Gland Papillary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07823439not yet recruiting Pattern and Surgical Outcome of Papillary Thyroid Cancer at Sohag University Hospitals · condition mapped ALIAS · 213 trials mapped (79 active)	—	—	Thyroid Gland Papillary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07485569Phase 1 · active not recruiting Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · condition mapped ALIAS · 213 trials mapped (79 active)	—	—	Poorly Differentiated Thyroid Gland Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00001160recruiting Studies on Tumors of the Thyroid · condition mapped ALIAS · 213 trials mapped (79 active)	—	—	Thyroid Gland Oncocytic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02152995Phase 2 · active not recruiting Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 213 trials mapped (79 active)	—	—	Poorly Differentiated Thyroid Gland Carcinoma	1	Observed	clinicaltrials	graph →

Head and Neck Adenocarcinoma studied in …STUDIED_INderived10 of 213show all (up to 200)

→ studied in

NCT05575440terminated

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 213 trials mapped (79 active)

—

Observed

Differentiated Thyroid Gland Carcinoma

→ studied in

NCT06475989Phase 3 · recruiting

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer · condition mapped CURATED_BROADER · 213 trials mapped (79 active)

—

Observed

Differentiated Thyroid Gland Carcinoma

→ studied in

NCT04522570NA · completed

Thermal Ablation of Cervical Metastases From Thyroid Carcinoma · condition mapped ALIAS · 213 trials mapped (79 active)

—

Observed

→ studied in

NCT06176989Phase 2 · recruiting

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors · condition mapped CURATED_BROADER · 213 trials mapped (79 active)

—

Sinonasal Adenocarcinoma

Observed

Thyroid Gland Follicular Carcinoma

→ studied in

NCT04544111Phase 2 · active not recruiting

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer · condition mapped ALIAS · 213 trials mapped (79 active)

—

Observed

→ studied in

NCT07140757recruiting

Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers · condition mapped ALIAS · 213 trials mapped (79 active)

—

Observed

→ studied in

NCT07823439not yet recruiting

Pattern and Surgical Outcome of Papillary Thyroid Cancer at Sohag University Hospitals · condition mapped ALIAS · 213 trials mapped (79 active)

—

Observed

Poorly Differentiated Thyroid Gland Carcinoma

→ studied in

NCT07485569Phase 1 · active not recruiting

Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · condition mapped ALIAS · 213 trials mapped (79 active)

—

Observed

Thyroid Gland Oncocytic Carcinoma

→ studied in

NCT00001160recruiting

Studies on Tumors of the Thyroid · condition mapped ALIAS · 213 trials mapped (79 active)

—

Observed

Poorly Differentiated Thyroid Gland Carcinoma

→ studied in

NCT02152995Phase 2 · active not recruiting

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 213 trials mapped (79 active)

—

Observed